# Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients

> **NCT05670054** · PHASE3 · UNKNOWN · sponsor: **Mansoura University** · enrollment: 116 (estimated)

## Conditions studied

- Breast Cancer Stage IV

## Interventions

- **DRUG:** comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival

## Key facts

- **NCT ID:** NCT05670054
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2023-10-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05670054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05670054, "Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05670054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*